MARKET

MNPR

MNPR

Monopar Therapeutics Inc
NASDAQ
85.24
-3.61
-4.06%
After Hours: 85.28 +0.05 +0.05% 19:32 09/25 EDT
OPEN
89.58
PREV CLOSE
88.84
HIGH
90.00
LOW
85.06
VOLUME
105.83K
TURNOVER
--
52 WEEK HIGH
124.82
52 WEEK LOW
50.07
MARKET CAP
572.11M
P/E (TTM)
-39.2788
1D
5D
1M
3M
1Y
5Y
1D
H.C. Wainwright Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)
TipRanks · 5d ago
Weekly Report: what happened at MNPR last week (0914-0918)?
Weekly Report · 6d ago
Weekly Report: what happened at MNPR last week (0907-0911)?
Weekly Report · 09/14 10:26
Monopar Therapeutics Is Maintained at Overweight by Barclays
Dow Jones · 09/11 13:58
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145
Benzinga · 09/11 13:48
Monopar Therapeutics price target raised to $145 from $128 at Barclays
TipRanks · 09/11 09:30
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Monopar Therapeutics Inc (MNPR)
TipRanks · 09/11 09:20
Weekly Report: what happened at MNPR last week (0831-0904)?
Weekly Report · 09/07 10:19
More
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Webull offers Monopar Therapeutics Inc stock information, including NASDAQ: MNPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNPR stock methods without spending real money on the virtual paper trading platform.